Search results for "Bone Marrow"

showing 10 items of 538 documents

Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.

2016

To compare whole-body MRI (WB-MRI) with diffusion-weighted imaging (DWI), FDG-PET/CT, and bone marrow biopsy (BMB), for the evaluation of bone marrow involvement (BMI) in patients with newly diagnosed lymphoma.This retrospective study was approved by our Institutional Review Board. Two independent radiologists and one nuclear medicine specialist reviewed all WB-MRI and FDG-PET/CT scans prospectively performed on 104 patients with newly diagnosed lymphoma (53 males; 47 Hodgkin; mean age: 44 years; range, 15-86 years) between 2013 and 2015. The delay between imaging scans and BMBs was up to 10 days. The diagnostic accuracy of WB-MRI (1.5 Tesla MR scanner, with T1w, T2w-STIR, and DWI sequences…

AdultAged 80 and overMaleAdolescentLymphomaBiopsyReproducibility of ResultsstagingMiddle AgedMagnetic Resonance ImagingYoung Adultbone marrow biopsyDiffusion Magnetic Resonance ImagingBone MarrowFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyHumansFemaleWhole Body Imagingpositron emission tomography-computerized tomographyRadiopharmaceuticalsAgedRetrospective StudiesJournal of magnetic resonance imaging : JMRI
researchProduct

Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies

2015

In recent years, mesenchymal stromal cells (MSCs) have been largely investigated and tested as a new therapeutic tool for several clinical applications, including the treatment of different rheumatic diseases. MSCs are responsible for the normal turnover and maintenance of adult mesenchymal tissues as the result of their multipotent differentiation abilities and their secretion of a variety of cytokines and growth factors. Although initially derived from bone marrow, MSCs are present in many different tissues such as many peri-articular tissues. MSCs may exert immune-modulatory properties, modulating different immune cells in both in vitro and in vivo models, and they are considered immune-…

AdultCancer ResearchpathogenesiCellular differentiationImmunologyCell- and Tissue-Based TherapyBone Marrow CellsMesenchymal Stem Cell TransplantationRegenerative MedicineRegenerative medicineAutoimmune DiseaseAutoimmune DiseasesChondrocytesImmune systemIn vivoBone MarrowRheumatic DiseasesmedicineHumansImmunology and Allergyrheumatic diseaseGenetics (clinical)TransplantationOsteoblastsMesenchymal Stromal Cellbusiness.industryOsteoblastMesenchymal stem cellMesenchymal Stem CellsCell DifferentiationCell BiologyChondrocyteClinical trialmedicine.anatomical_structureregenerative therapyOncologymesenchymal stromal cells; pathogenesis; regenerative therapy; rheumatic disease; Adult; Autoimmune Diseases; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell- and Tissue-Based Therapy; Chondrocytes; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells; Osteoblasts; Regenerative Medicine; Rheumatic DiseasesImmunologyBone Marrow CellBone marrowStem cellbusinessHuman
researchProduct

HSP10 selective preference for myeloid and megakaryocytic precursors in normal human bone marrow

2004

Heat shock proteins (HSPs) constitute a heterogeneous family of proteins involved in cell homeostasis. During cell life they are involved in harmful insults, as well as in immune and inflammatory reactions. It is known that they regulate gene expression, and cell proliferation, differentiation and death. HSP60 is a mitochondrial chaperonin, highly preserved during evolution, responsible of protein folding. Its function is strictly dependent on HSP10 in both prokaryotic and eukaryotic elements. We investigated the presence and the expression of HSP60 and HSP10 in a series of 20 normal human bone marrow specimens (NHBM) by the means of immunohistochemistry. NHBM showed no expression of HSP60,…

AdultHsp 10 bone marrowCell DifferentiationChaperonin 60Middle AgedImmunohistochemistrylcsh:Biology (General)Gene Expression RegulationBone MarrowChaperonin 10HumansCell Lineagelcsh:QH301-705.5MegakaryocytesMyeloid Progenitor CellsAged
researchProduct

Selective Depletion of Alloreactive T Lymphocytes Using Patient-Derived Nonhematopoietic Stimulator Cells in Allograft Engineering

2008

Background. Selective depletion of alloreactive T cells in vitro results in efficient graft-versus-host disease prophylaxis in allogeneic hematopoietic stem-cell transplantation, but it is accompanied by increased recurrence of leukemia. To spare donor T-cell-mediated graft-versus-leukemia immunity against hematopoiesis-restricted minor histocompatibility (minor-H) antigens, we explored the use of patient-derived nonhematopoietic antigen-presenting cells (APC) as allogeneic stimulators for selective allodepletion in leukemia-reactive donor T-cell lines. Methods. Primary keratinocytes, dermal fibroblasts, and bone marrow fibroblasts were generated from skin biopsies and diagnostic bone marro…

AdultKeratinocytesT-LymphocytesLymphocyteGraft vs Host DiseaseHuman leukocyte antigenLymphocyte DepletionInterferon-gammaTumor Necrosis Factor Receptor Superfamily Member 9AntigenAntigens CDmedicineHumansTransplantation HomologousSkinB-LymphocytesHLA-D AntigensTransplantationCD40Tissue EngineeringbiologyHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationDermisT lymphocyteFibroblastsmedicine.diseaseLeukemiamedicine.anatomical_structureEpidermal CellsImmunologybiology.proteinBone marrowEpidermisCD8Transplantation
researchProduct

Bone marrowVEGFCexpression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with sur…

2018

Vascular endothelial growth factor C (VEGFC) stimulates leukemia cell proliferation and survival, and promotes angiogenesis. We studied VEGFC expression in bone marrow samples from 353 adult acute myeloid leukemia (AML) patients and its relationship with several clinical, cytogenetic, and molecular variables. We also studied the expression of 84 genes involved in VEGF signaling in 24 patients. We found that VEGFC expression was higher in AML patients with myelodysplasia-related changes (AML-MRC) than in patients with non-AML-MRC. We also found an association between VEGFC expression and the patient cytogenetic risk group, with those with a worse prognosis having higher VEGFC expression leve…

AdultMale0301 basic medicineCancer ResearchAdolescentAngiogenesisVascular Endothelial Growth Factor CKaplan-Meier EstimateVEGFC expressionYoung Adult03 medical and health sciences0302 clinical medicineKDRBone Marrowhemic and lymphatic diseasesNeuropilin 1Biomarkers TumormedicineNRP1HumansGeneFLT1AgedChromosome AberrationsAcute myeloid leukemiaVascular Endothelial Growth Factor Receptor-1Cell growthbusiness.industryAdult Acute Myeloid LeukemiaHematologyVEGF signalingMiddle AgedPrognosismedicine.diseaseVascular Endothelial Growth Factor Receptor-2Neuropilin-1Leukemia Myeloid AcuteLeukemia030104 developmental biologymedicine.anatomical_structureOncologyVascular endothelial growth factor CMyelodysplastic Syndromes030220 oncology & carcinogenesisCancer researchFemaleBone marrowbusinessLeukemia & Lymphoma
researchProduct

Bone marrow after autologous blood stem cell transplantation and total body irradiation: magnetic resonance and chemical shift imaging.

1993

Magnetic resonance studies of the lumbar, pelvic, and femoral bone marrow were performed in 10 patients after autologous blood stem cell transplantation, including total body irradiation and myeloablative chemotherapy. The posttreatment interval varied between 2 and 6 yr. The appearance on T1-weighted images and the quantitative data obtained from chemical shift imaging (relative fat signal) were compared to 10 age-matched healthy volunteers. The classification of the T1-weighted images yielded no significant differences between the two groups. Chemical shift imaging by determination of the relative fat signal was able to detect a significant fatty replacement of the patients' lumbar (p < .…

AdultMaleAdolescentmedicine.medical_treatmentBiomedical EngineeringBiophysicsBlood cellLumbarBone MarrowmedicineHumansRadiology Nuclear Medicine and imagingFemurChildPelvic BonesChemotherapyLeukemiaLumbar Vertebraemedicine.diagnostic_testChemistrybusiness.industryHematopoietic Stem Cell TransplantationMagnetic resonance imagingTotal body irradiationMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingTransplantationmedicine.anatomical_structureAcute DiseaseFemaleBone marrowStem cellNuclear medicinebusinessWhole-Body IrradiationMagnetic resonance imaging
researchProduct

Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC …

1998

Despite the wide use of G-CSF for mobilization of PBPC the best dose and schedule of G-CSF has not been definitively established. In this study we have compared three different schedules of G-CSF for mobilization of PBPC in normal donors including a single daily dose of 10 microg/kg/day for 5 days (21 donors) and doses of 6 (21 donors) or 8 microg/kg/12 h (6 donors) for 5 days. We demonstrate that G-CSF at doses of 6 and 8 microg/kg/12 h mobilizes significantly more CD34+ cells/ml of blood (83.3 +/- 6.7 and 121 +/- 6.9, respectively) than 10 microg/kg/day (71.6 +/- 6.5). Mobilization with 6 or 8 microg/kg/12 h of G-CSF was also associated with collection of significantly more CD34+ cells in…

AdultMaleAdolescentmedicine.medical_treatmentBlood volumeHematopoietic stem cell transplantationDrug Administration ScheduleAndrologyGranulocyte Colony-Stimulating FactorHumansTransplantation HomologousMedicinePlateletProgenitor cellChildAgedTransplantationMobilizationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationBlood Cell CountGranulocyte colony-stimulating factorTransplantationmedicine.anatomical_structureImmunologyBlood Component RemovalFemaleBone marrowbusinessBone Marrow Transplantation
researchProduct

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acut…

2013

Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of the human equilibrative nucleoside transporter 1 (hENT1). This phase II study tested whether the hENT1 blast expression level can be used as a predictive marker for cytarabine response and if the efficacy of elacytarabine is independent of hENT1 expression. A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. The overall response rate (ORR) was 41% and the safety profile was man…

AdultMaleCancer ResearchAdolescentPhases of clinical researchGene ExpressionPharmacologyNucleoside transporterEquilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 1Young AdultBone MarrowAntineoplastic Combined Chemotherapy ProtocolsmedicineIdarubicinHumansAgedPredictive markerbiologyElacytarabinebusiness.industryCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyInduction ChemotherapyMiddle AgedLeukemia Myeloid AcuteTreatment OutcomeOncologybiology.proteinCytarabineFemalebusinessIdarubicinmedicine.drugLeukemialymphoma
researchProduct

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.

2008

Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen…

AdultMaleCancer ResearchDNA ComplementaryT-LymphocytesAntigen-Presenting CellsEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyAntigenhemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCytotoxic T cellHumansIn Situ Hybridization FluorescenceReverse Transcriptase Polymerase Chain ReactionHematologyNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseTransplantationHaematopoiesismedicine.anatomical_structureOncologyImmunologyBone marrowStem cellChronic myelogenous leukemiaLeukemia
researchProduct

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3…

2008

Activating mutations of FLT3 are found in approximately one-third of acute myeloid leukemia (AML)-cases and are considered to represent an attractive therapeutic target. In this study, we report that the hydroxystyryl-acrylonitrile compound LS104 inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells in vitro. Immunoblot and phosphoprotein-FACS analysis demonstrated inhibiton of phosphorylation of FLT3-ITD and of its downstream targets. In pharmacokinetic studies, a rapid and dose dependent cellular uptake of LS104 lasting up to 11h could be demonstrated. Combination of LS104 with chemotherapeutic agents markedly enhanced cytotoxic effects. Recently, a…

AdultMaleCancer ResearchDaunorubicinmedicine.drug_classBlotting WesternFluorescent Antibody TechniqueApoptosisPharmacologyReceptor tyrosine kinaseTyrosine-kinase inhibitorStyrenesColony-Forming Units AssayMiceBone Marrowhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedCD135AnimalsHumansPoint MutationTissue DistributionAgedCell ProliferationAged 80 and overbiologyAcrylonitrileDaunorubicinCytarabineMyeloid leukemiaCell DifferentiationHematologyMiddle Agedmedicine.diseaseLeukemiaLeukemia Myeloid AcuteOncologyfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3Cytarabinebiology.proteinCancer researchDrug Therapy CombinationFemalemedicine.drugSignal TransductionLeukemia research
researchProduct